Corbus Pharmaceuticals Holdings, Inc. (CRBP) Stock
NMQ · CRBP
7.48
Fundamentals
Market cap
$144.67M
Price / Earnings ratio
-1.4x
Price / Sales ratio
N/A
Price / Book ratio
1.4x
Return on assets
-0.6%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
SectorHealthcare
IndustryBiotechnology
Employees36
CEODr. Yuval Cohen Ph.D.
IPO DateApr 16, 2015
HeadquartersNorwood, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Yuval Cohen Ph.D. | CEO & Director | 1975 |
| Mr. Sean F. Moran CPA, M.B.A. | Chief Financial Officer | 1958 |
| Dr. Ian Hodgson B.Sc., Ph.D. | Chief Operating Officer | 1973 |
| Mr. G. Scott Goeken J.D., M.S. | General Counsel & Corporate Secretary | — |
| Ms. Christina Bertsch M.A. | Vice President of Human Resources | — |
| Mr. Nishant C. Saxena | Chief Business Officer | — |
| Dr. Leonardo Viana Nicacio M.D. | Chief Medical Officer | 1978 |
Fundamentals
Valuation
Market cap$144.67M
Price-to-sales ratioN/A
Price-to-book value1.37
Price-earnings ratio-1.40
Return on Equity-71.00%
Return on SalesN/A
Return on AssetsN/A
PEG ratio0.00
Earnings Per Share
Earnings Per Share$-6.11
Income Statement
Average volume1,250,185
EBITDA$-84.33M
1 year high (52w)$20.56
1 year low (52w)$6.33
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



